Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1885 1
1886 1
1889 2
1890 1
1903 1
1906 1
1927 2
1957 1
1973 1
1976 2
1979 3
1981 2
1983 1
1985 1
1986 1
1988 1
1989 2
1990 1
1992 2
1993 1
1994 1
1995 1
1996 1
1997 6
1998 8
1999 15
2000 18
2001 16
2002 28
2003 40
2004 48
2005 76
2006 104
2007 80
2008 106
2009 110
2010 123
2011 123
2012 152
2013 130
2014 126
2015 135
2016 167
2017 161
2018 167
2019 163
2020 179
2021 179
2022 157
2023 164
2024 79

Text availability

Article attribute

Article type

Publication date

Search Results

2,493 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Newton-Youens
Page 1
Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND).
Shi VY, Bhutani T, Fonacier L, Deleuran M, Shumack S, Valdez H, Zhang F, Chan GL, Cameron MC, Yin NC. Shi VY, et al. J Am Acad Dermatol. 2022 Aug;87(2):351-358. doi: 10.1016/j.jaad.2022.04.009. Epub 2022 Apr 16. J Am Acad Dermatol. 2022. PMID: 35439608 Free article. Clinical Trial.
METHODS: Patients with moderate-to-severe atopic dermatitis received abrocitinib 200 mg or 100 mg once daily in JADE EXTEND (phase 3 extension) after dupilumab in double-blind, placebo-controlled phase 3 JADE COMPARE. ...LIMITATIONS: Short-term, 12-week analysis; no …
METHODS: Patients with moderate-to-severe atopic dermatitis received abrocitinib 200 mg or 100 mg once daily in JADE EXTEND (phase 3 …
Brief Academic Review and Clinical Practice Guidelines for Pediatric Atopic Dermatitis.
Yang YB, Gohari A, Lam J. Yang YB, et al. Curr Pediatr Rev. 2021;17(3):229-237. doi: 10.2174/1573396316999200820163434. Curr Pediatr Rev. 2021. PMID: 32867653 Review.
Although not currently approved for the treatment of AD, Janus-kinase (JAK) inhibitors represent a promising new class of biologics with recently completed phase III clinical trials (JADE-- MONO1/2)....
Although not currently approved for the treatment of AD, Janus-kinase (JAK) inhibitors represent a promising new class of biologics with rec …
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.
Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, Gubelin W, Simpson EL, Valenzuela F, Criado PR, Lebwohl MG, Feeney C, Khan T, Biswas P, DiBonaventura M, Valdez H, Cameron MC, Rojo R. Blauvelt A, et al. J Am Acad Dermatol. 2022 Jan;86(1):104-112. doi: 10.1016/j.jaad.2021.05.075. Epub 2021 Aug 17. J Am Acad Dermatol. 2022. PMID: 34416294 Free article. Clinical Trial.
OBJECTIVE: We evaluated the maintenance of abrocitinib-induced response with continuous abrocitinib treatment, dose reduction or withdrawal, and response to treatment reintroduction following flare (JAK1 Atopic Dermatitis Efficacy and Safety [JADE] REGIMEN: National Clinic …
OBJECTIVE: We evaluated the maintenance of abrocitinib-induced response with continuous abrocitinib treatment, dose reduction or withdrawal, …
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
Reich K, Silverberg JI, Papp KA, Deleuran M, Katoh N, Strober B, Beck LA, de Bruin-Weller M, Werfel T, Zhang F, Biswas P, DiBonaventura MD, Chan G, Johnson S, Farooqui SA, Kerkmann U, Clibborn C. Reich K, et al. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):2056-2066. doi: 10.1111/jdv.19280. Epub 2023 Jul 11. J Eur Acad Dermatol Venereol. 2023. PMID: 37335885
OBJECTIVE: To evaluate the abrocitinib efficacy up to 48 weeks and long-term safety in patients with moderate-to-severe AD. METHODS: JADE EXTEND (NCT03422822) is an ongoing, phase 3, long-term extension study that enrolled patients from previous abrocitinib AD trials. This …
OBJECTIVE: To evaluate the abrocitinib efficacy up to 48 weeks and long-term safety in patients with moderate-to-severe AD. METHODS: JADE …
Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial.
Flohr C, Cork MJ, Ardern-Jones MR, Eichenfield LF, Barbarot S, Feeney C, Rojo R, Lazariciu I, Nesnas J. Flohr C, et al. J Dermatolog Treat. 2023 Dec;34(1):2200866. doi: 10.1080/09546634.2023.2200866. J Dermatolog Treat. 2023. PMID: 37036183 Free article. Clinical Trial.
OBJECTIVE: To evaluate response maintenance with continuous-/reduced-dose abrocitinib or withdrawal and response to treatment reintroduction after flare in adolescent and adult participants in JADE REGIMEN (NCT03627767). METHODS: Adolescents (12-17 years) and adults with m …
OBJECTIVE: To evaluate response maintenance with continuous-/reduced-dose abrocitinib or withdrawal and response to treatment reintroduction …
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
Ständer S, Kwatra SG, Silverberg JI, Simpson EL, Thyssen JP, Yosipovitch G, Zhang F, Cameron MC, Cella RR, Valdez H, DiBonaventura M, Feeney C. Ständer S, et al. Am J Clin Dermatol. 2023 Jan;24(1):97-107. doi: 10.1007/s40257-022-00738-4. Epub 2022 Dec 13. Am J Clin Dermatol. 2023. PMID: 36512175 Free PMC article. Clinical Trial.
BACKGROUND: Abrocitinib, an oral Janus kinase 1 inhibitor, provided significant itch relief by week 2 in patients with moderate-to-severe atopic dermatitis (AD) in the phase III JADE COMPARE trial. OBJECTIVES: This post-hoc analysis of JADE COMPARE aimed to further …
BACKGROUND: Abrocitinib, an oral Janus kinase 1 inhibitor, provided significant itch relief by week 2 in patients with moderate-to-severe at …
Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice.
Gooderham MJ, Pink AE, Simpson EL, Silverberg JI, Güler E, Watkins M. Gooderham MJ, et al. Dermatol Ther (Heidelb). 2023 Sep;13(9):1893-1907. doi: 10.1007/s13555-023-00948-6. Epub 2023 Jul 23. Dermatol Ther (Heidelb). 2023. PMID: 37482564 Free PMC article. Review.
This review summarizes the efficacy and safety of abrocitinib 100 mg once daily for patients with moderate-to-severe AD based on data from the pivotal phase 3 studies of the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) clinical program, JADE MONO-1 (NCT03349060 …
This review summarizes the efficacy and safety of abrocitinib 100 mg once daily for patients with moderate-to-severe AD based on data from t …
Jade-1: its structure, regulation and functions in the renal cancer.
Zhang YC, Du WQ, Zhang RY, Zheng JN, Pei DS. Zhang YC, et al. Curr Mol Med. 2016;16(1):63-9. doi: 10.2174/1566524016666151222144511. Curr Mol Med. 2016. PMID: 26695694 Review.
Jade-1 is also deemed to be a candidate of transcriptional co-activator associated with histone acetyltransferase (HAT) activity. This review focuses on the anticancer role of Jade-1 in clear cell renal carcinoma and the inhibitory effect of Jade-1 on cystic …
Jade-1 is also deemed to be a candidate of transcriptional co-activator associated with histone acetyltransferase (HAT) activity. Thi …
The efficacy of jade moxibustion in knee osteoarthritis.
Chen L, Huang Z, Cheng K, Wu F, Deng H, Lin L, Zhao L, Shen X. Chen L, et al. Medicine (Baltimore). 2020 Apr;99(17):e19845. doi: 10.1097/MD.0000000000019845. Medicine (Baltimore). 2020. PMID: 32332638 Free PMC article.
INTRODUCTION: This study aims to compare clinical effect between Jade moxibustion and traditional moxibustion, and to determine the clinical effect of Jade moxibustion on knee osteoarthritis (KOA). ...Jade moxibustion group: The affected knee of the subjects …
INTRODUCTION: This study aims to compare clinical effect between Jade moxibustion and traditional moxibustion, and to determine the c …
Jade.
Mariano NA. Mariano NA. Ann Intern Med. 2010 Jul 6;153(1):56. doi: 10.7326/0003-4819-153-1-201007060-00014. Ann Intern Med. 2010. PMID: 20621904 No abstract available.
2,493 results